MTOR and renal cell carcinoma: Targeted therapy such as tyrosine kinase inhibitors and mammalian target of rapamycin (mTOR) inhibitors have been introduced recently, but there are no data to indicate that it is curative, and most patients who undergo this therapy eventually relapse, leading to death from RCC [3].